ild's Name: Birthdate:			Male/Female School:			
Last,	First	month/day	//year			
Address			Phone:	Gra	ade:	
Street	City	Zip				
		-	ublic Health Depai essment for Schoo			
This form must be comp	oleted by a licensed h	nealth profess	sional in the U.S. and r	eturned to the	child's so	chool.
Was your child born with an elevated rat		d (for more tha	n one month) to a coun	try	□ Yes	□ No
2. Has your child been in	n close contact to anyo	one with TB dis	sease in their lifetime?		□ Yes	□ No
3. Is your child immunosuppressed; current, or planned? (e.g., due to HIV infection, organ						
transplant, treatment with TNF-alpha antagonist or high-dose systemic steroids (e.g., prednisone ≥ 15 mg/day for ≥ 2 weeks).					☐ Yes	□ No
*Most countries other that This does not include tou significant contact with th	rist travel for <1 month					
If YES, to any of the about tuberculin skin test (TST since last documented n) unless there is either	r 1) a documer	nted prior positive IGRA	or TST or 2) no	new risk	factors
All children with a current (CXR; posterior-anterior a documented prior treatme children who have a posit normal, the child should be	and lateral for children ent for TB disease, do ive TST and negative	<5 years old is cumented prio IGRA. If there	s recommended). CXR r treatment for latent TE are no symptoms or siç	is not required f B infection, or BC gns of TB diseas	or childre CG-vaccir e and the	n with nated
Enter test results for all	children with a posit	ive risk asses	sment:			
Date of (IGRA)			Result: Negative	☐ Positive ☐	I Indeterr	ninate
Tuberculin Skin Test (T	ST/Mantoux/PPD)		Indurationmm			
Date placed:	Date read:		Result: Negative	☐ Positive		
Chest X-Ray Date: Impression: □ Normal □ Abnormal						
LTBI Treatment Start D ☐ Rifampin d	aily - 4 months		☐ Prior TB/LTBI tre	atment (Rx & du	ration):	_
	tifapentine - weekly X ^r aily - 9 months	12 weeks	☐ Treatment medic	ally contraindicat	ted	
☐ Isoniazid a advice mor	nd Rifampin daily - 3		□ Declined against	medical		-
Please check one of the		n:				
☐ Child has a risk fac ☐ Child has no new ri	tor, has been evaluate sk factors since last ne	ed for TB and is egative IGRA/1	loes not require a TB te free of active TB disea ST and has no sympton scheduled on:	se. ns.		
		Health Car	e Provider Signature, Title			Date
Name/Title of Health Pr Facility/Address: Phone number:	ovider:					

County of Santa Clara

Public Health Department

Tuberculosis Prevention & Control Program 976 Lenzen Avenue, Suite 1700 San José, CA 95126 408.885.2440



Testing Methods

An Interferon Gamma Release Assay (IGRA, i.e., QuantiFERON or T-SPOT.TB) or Mantoux tuberculin skin test (TST) should be used to test those at increased risk. An IGRA can be used in all children ≥ 2 years old and is preferred in BCG-vaccinated children to avoid a false positive TST result. A TST of ≥10mm induration is considered positive. If a child has had contact with someone with active TB disease (yes to question 2 on reverse), or the child is immunosuppressed, then TST ≥5 mm is considered positive. If a BCG-vaccinated child has a positive TST, and an IGRA is subsequently performed and is negative, testing is considered negative unless the child was exposed to someone with TB disease or is immunosuppressed. For immunosuppressed children, screening should be performed by CXR in addition to a TST/IGRA (consider doing both) and symptom review. TB screening can be falsely negative within 8 weeks after exposure, so are best obtained 8 weeks after last exposure.

Evaluation of Children with Positive TB Tests

- All children with a positive IGRA/TST result must have a medical evaluation, including a CXR (posterior-anterior
 and lateral is recommended for children <5 years old). A CXR is not required for a positive TST with negative
 IGRA in a BCG-vaccinated child, or if the child has documentation of prior treatment for TB disease or treatment
 for latent TB infection.
- For children with TB symptoms (e.g., cough for >2-3 weeks, shortness of breath, hemoptysis, fever, weight loss, night sweats) or an abnormal CXR consistent with active TB disease, report to the County of Santa Clara Public Health Department TB Program within one day. The child will need to be evaluated for TB disease with sputum AFB smears/cultures and nucleic acid amplification testing. A negative TST or IGRA does not rule out active TB disease in a patient with symptoms or signs of TB disease. The child cannot enter school unless active TB disease has been excluded or treatment has been initiated.
- If there are no symptoms or signs of TB disease and the CXR is normal, the child should be treated for latent TB infection (LTBI). Do not treat for LTBI until active TB disease has been excluded.
- Short-course regimens are preferred (except in persons for whom there is a contraindication, such as a drug
 interaction or contact to a person with drug-resistant TB) due to similar efficacy and higher treatment
 completion rates as compared with 9 months of daily isoniazid.

Treatment Regimens for Latent TB Infection

- Rifampin 15 20 mg/kg (max. 600 mg) daily for 4 months
- 12-dose Weekly Isoniazid/Rifapentine (3HP) Regimen:
 - Isoniazid

2-11 years old: 25 mg/kg rounded up to nearest 50 or 100 mg (max. 900 mg) ≥ 12 years old: 15 mg/kg rounded up to nearest 50 or 100 mg (max. 900 mg)

Rifapentine

10.0-14.0 kg: 300 mg 14.1-25.0 kg: 450 mg 25.1-32.0 kg: 600 mg 32.1-50.0 kg: 750 mg >50 kg: 900 mg

- Vitamin B6 50 mg weekly
- Isoniazid 10 mg/kg (range, 10-15 mg/kg; max. 300 mg) daily for 9 months. Recommended pyridoxine dosage is 25 mg for school-aged children (or 1-2 mg/kg/day).
- Isoniazid and Rifampin daily for 3 months: Children: Isoniazid 10-20 mg/kg (300 mg maximum) Rifampin 15-20 mg/kg; (600 mg maximum)

Board of Supervisors: Mike Wasserman, Cindy Chavez, Otto Lee, Susan Ellenberg, S. Joseph Simitian, County Executive: Jeffrey V. Smith